Click Here to Go Directly to the Story

 
 


U.S. EDITION
Full Table of Contents
Cover Story
Up Front
Readers Report
Corrections & Clarifications
Books
Technology & You
Economic Viewpoint
Business Outlook
News: Analysis & Commentary
In Business This Week

Washington Outlook
Science & Technology
Information Technology
The Corporation
Legal Affairs
Finance
Developments to Watch
Management
BusinessWeek Investor
Dividends

The Barker Portfolio
Inside Wall Street
Figures of the Week
Editorials


INTERNATIONAL EDITIONS
International -- Int'l Cover Story
International -- Readers Report
International -- Asian Business
International -- European Business
International -- Latin America
International -- Int'l Figures of the Week




DECEMBER 23, 2002

INSIDE WALL STREET

Stericycle's Wounds

 
By Gene G. Marcial
Gene Marcial

  STORY TOOLS
Printer-Friendly Version
E-Mail This Story

Related Items Chart: Infection May Be Setting In


INSIDE WALL STREET

Stericycle's Wounds

Del Monte Could Ripen Into a Real Peach

Siga Technologies Takes Aim at Smallpox

Inside Wall Street Archive

When Stericycle (SRCL ) was featured in this column on May 27, the Street was high on the top U.S. provider of medical-waste disposal. The shares, trading at split-adjusted 36, rose to 40 by mid-June. Since then, however, they have sagged to 31, because of antitrust ills. Many analysts remain bullish--but not Evan Sturza of Sturza's Institutional Research, who thinks Stericycle is overvalued relative to its peers in waste management, and rates it a sell. He says the stock is worth 22. One hedge-fund manager shorting the stock sees Stericycle going even lower--to 16 in 12 months.


This pro's major concern is that Stericycle's settlement in August of an antitrust investigation in Arizona--and a similar one in Utah--"could open up a Pandora's box [in other states]." The probes were sparked by Stericycle's 1997 purchase of the Arizona medical-waste assets of Browning-Ferris Industries and its sale of Utah and Colorado properties to Browning. Stericycle agreed to pay Arizona $320,000 in civil penalties to settle and hopes to do the same with Utah. Although CEO Mark Miller says he is unaware of any other antitrust inquiries, Sturza feels the settlement "highlights Stericycle's anticompetitive pricing practices." So he expects more trouble from other state attorneys general.

The shorts are also alarmed by corporate insider selling at Stericycle. In November alone, insiders sold stock worth $22 million. Among them: Chairman Jack Schuler and Miller, who sold at 34 to 36 for a total of $8.8 million and $4.5 million, respectively. Miller says that despite the selling, management still owns 18% of the stock. Street consensus earnings estimates for Stericycle: $1.05 a share for 2002 and $1.29 for 2003.

Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.



By Gene G. Marcial


Get BusinessWeek directly on your desktop with our RSS feeds.XML

Add BusinessWeek news to your Web site with our headline feed.

Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video.

To subscribe online to BusinessWeek magazine, please click here.

Learn more, go to the BusinessWeekOnline home page

Back to Top

DECEMBER
TODAY'S MOST POPULAR STORIES

  1. Why Qualcomm Folded to Nokia
  2. America for Sale
  3. Nobody Loves a Three-Year-Old SUV
  4. Microsoft: What Web Strategy?
  5. Sales of Foreclosed Homes Are Up Nationwide

Get Free RSS Feed >>
  MARKET INFO
DJIA 11370.69 +21.41
S&P 500 1257.76 +5.22
Nasdaq 2310.53 +30.42

Portfolio Service Update

Stock Lookup

Enter name or ticker



Media Kit | Special Sections | MarketPlace | Knowledge Centers
McGraw-Hill Cos.